Hye Sung Won

Jul 19, 2024 | arthritis-research.biomedcentral.com | Hye Sung Won |Dae Hyun |Su Jin |Hanyang College

ReferencesSmolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023–38. Article  CAS  PubMed  Google Scholar  Figus FA, Piga M, Azzolin I, et al. Rheumatoid arthritis: extra-articular manifestations and comorbidities. Autoimmun Rev. 2021;20:102776. Article  CAS  PubMed  Google Scholar  Ellman P, Ball RE. Rheumatoid disease with joint and pulmonary manifestations. Br Med J. 1948;2:816–20.

Jul 17, 2024 | arxiv.org | Hye Sung Won

Feb 15, 2024 | academic.oup.com | Hye Sung Won

To assess the effectiveness of tofacitinib vs tumour necrosis factor inhibitors (TNFi) in Korean patients with rheumatoid arthritis (RA). The study used data from a single academic referral hospital's registries of biologic disease-modifying anti-rheumatic drugs (bDMARDs) and tofacitinib and examined remission rates based on the disease activity score (DAS)28-erythrocyte sedimentation rate (ESR) after 12 months.